Compare Mattel Inc (MAT) vs Pfizer Inc (PFE) Price & Performance

Mattel (MAT) trades at $14.165, down 0.94% today, with a bullish technical signal supported by moving averages. The stock shows attractive valuation with a P/E of 9.17 and P/S of 0.84, while recent earnings have been mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Revenue remains stable around $5.4B, and the company maintains strong brand collaborations, as seen with recent Hot Wheels and Barbie partnerships.

Outlook is cautiously optimistic given undervaluation and analyst consensus, but risks include stagnant sales, debt levels, and recent negative cash flow trends. The consensus price target is $14.60, suggesting limited upside from current levels, with investor sentiment divided between value opportunity and near-term headwinds.

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a bullish technical signal despite near-term resistance. The company maintains solid fundamentals with a P/E of 19.12, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning for a catalyst-rich 2026.

The outlook is cautiously optimistic, supported by a $28.25 analyst price target and a 38.46% buy rating. Key opportunities include dividend stability and pipeline progress, while risks involve patent cliffs and revenue normalization post-COVID. The stock presents a value proposition for income-focused investors amid ongoing business transformation.